Dronedarone News and Research

RSS
Dronedarone (also known as Multaq) is a drug used mainly for the indication of cardiac arrhythmias (irregular heartbeat).
Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Boehringer Ingelheim announces FDA approval of Praxbind (idarucizumab)

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Boehringer signs agreement with Brigham to conduct long-term study program on oral anticoagulants

Dabigatran decreases risk of recurrent venous thromboembolism

Dabigatran decreases risk of recurrent venous thromboembolism

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Updated U.S. prescribing information for Boehringer Ingelheim’s Pradaxa

Pradaxa use does not appear to increase serious bleeding

Pradaxa use does not appear to increase serious bleeding

Study supports catheter ablation as first-line treatment for paroxysmal atrial fibrillation

Study supports catheter ablation as first-line treatment for paroxysmal atrial fibrillation

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

One in three AF patients at high risk of stroke are not being prescribed VKA therapy

ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial

ESC to produce focused update on AF Guidelines following early termination of PALLAS Trial

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Lead investigator to discuss growing impact of AFib on US health care costs and resources

CCS presents new 2010 Atrial Fibrillation Guidelines

CCS presents new 2010 Atrial Fibrillation Guidelines

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Antiarrhythmic drug dronedarone less effective and causes fewer side effects

Antiarrhythmic drug dronedarone less effective and causes fewer side effects

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

Physician scientists present new findings on aspirin therapy, atrial fibrillation drug therapy and LVAD

Physician scientists present new findings on aspirin therapy, atrial fibrillation drug therapy and LVAD

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Multaq approved for atrial fibrillation by FDA

Multaq approved for atrial fibrillation by FDA

FDA approves Multaq tablets (dronedarone) to treat atrial fibrillation

FDA approves Multaq tablets (dronedarone) to treat atrial fibrillation